exudative age-related macular degeneration
Ophthalmology · 2006–2006
3decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| anecortave acetate treatment by specialist ophthalmologists of exudative age related macular degeneration (AMD), where there is a classic component | Mar 2006 | Not recommended | no section in document |
| anecortave acetate treatment of subfoveal choroidal neovascularisation (CNV) due to exudative age related macular degeneration (AMD) where the CNV is composed predominantly… | Nov 2006 | Recommended with restriction | no section in document |
| anecortave acetate Treatment of subfoveal choroidal neovascularisation (CNV) due to exudative age-related macular degeneration (AMD) where the CNV is composed predominantly… | Nov 2006 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.